Categories: News

Kura Oncology to Participate in Four Upcoming Investor Conferences

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive officer is scheduled to participate in four upcoming virtual investor conferences:

  • A fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference at 2:20 p.m. ET / 11:20 a.m. PT on February 25, 2021;
  • A leukemias panel discussion at the Cowen 41st Annual Health Care Conference at 11:40 a.m. ET / 8:40 a.m. PT on March 3, 2021;
  • A pre-recorded fireside chat at the H.C Wainwright Global Life Sciences Conference available on-demand starting at 7:00 a.m. ET / 4:00 a.m. PT on March 9, 2021; and
  • A company presentation at the Barclays Virtual Global Healthcare Conference on March 10, 2021 at 4:10 p.m. ET / 1:10 p.m. PT.

Live audio webcasts of the SVB Leerink and Barclays events will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available for 30 days following the events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

 

Staff

Recent Posts

Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

2 hours ago

FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers

NEW CANAAN, Conn., Dec. 22, 2025 /PRNewswire/ -- FlyteHealth, a national leader in integrated cardio-kidney-metabolic care,…

2 hours ago

10 Days, 10 Ways to Spend FSA (Flexible Spending Account) Funds Before the December 31 Use-It-or-Lose-It Deadline, from FSA Store®

The clock is ticking on 2025 FSA funds, and as the use-it-or-lose-it deadline approaches, FSA…

2 hours ago

TraceLink Wins 2025 Merit Award — Recognized for Healthcare Innovation for the Third Consecutive Year

TraceLink has been named a winner of the 2025 Merit Awards for Healthcare Innovation, marking…

2 hours ago

NUCALM CELEBRATES RECORD-BREAKING DECEMBER WITH OVER 2 BILLION MINUTES USED AND LARGEST LIVE EVENT ACTIVATION EVER

Tony Robbins' "Date with Destiny" Event Drives Unprecedented Engagement with NuCalm TechnologyPALM BEACH, Fla., Dec.…

2 hours ago

Point-of-Care Is Just the Beginning: Doceree 360 Report Maps Three Strategic Imperatives for HCP Engagement Across All Digital Touchpoints

New Annual Report Reveals Opportunity for Pharma Marketers to Reach Physicians Throughout Entire Decision-Making Journey—From Learning…

2 hours ago